Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Precision Biosciences Inc (DTIL)

Precision Biosciences Inc (DTIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 53,691
  • Shares Outstanding, K 13,257
  • Annual Sales, $ 68,700 K
  • Annual Income, $ 7,170 K
  • EBIT $ -90 M
  • EBITDA $ -86 M
  • 60-Month Beta 1.20
  • Price/Sales 58.30
  • Price/Cash Flow N/A
  • Price/Book 3.11

Options Overview Details

View History
  • Implied Volatility 203.06% (-324.02%)
  • Historical Volatility 49.40%
  • IV Percentile 17%
  • IV Rank 15.14%
  • IV High 1,257.70% on 12/05/25
  • IV Low 14.92% on 12/16/25
  • Expected Move (DTE 32) 1.53 (37.78%)
  • Put/Call Vol Ratio 0.67
  • Today's Volume 25
  • Volume Avg (30-Day) 21
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 893
  • Open Int (30-Day) 834
  • Expected Range 2.52 to 5.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.21
  • Number of Estimates 1
  • High Estimate -0.21
  • Low Estimate -0.21
  • Prior Year -3.20
  • Growth Rate Est. (year over year) +93.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.75 +8.05%
on 01/12/26
5.04 -19.64%
on 12/17/25
-0.77 (-15.98%)
since 12/16/25
3-Month
3.75 +8.05%
on 01/12/26
8.82 -54.08%
on 10/29/25
-2.59 (-39.01%)
since 10/16/25
52-Week
3.75 +8.05%
on 01/12/26
8.82 -54.08%
on 10/29/25
-0.67 (-14.19%)
since 01/16/25

Most Recent Stories

More News
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy

Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts; Data updates expected at medical conferences in 2026 PBGENE-DMD expecting...

DTIL : 4.05 (+3.85%)
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases...

DTIL : 4.05 (+3.85%)
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet...

DTIL : 4.05 (+3.85%)
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies...

DTIL : 4.05 (+3.85%)
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

PBGENE-HBV, the first gene editing therapy designed to treat chronic Hepatitis B by directly targeting HBV cccDNA and integrated HBV DNA, showcased as the final oral presentation in the late-breaking...

DTIL : 4.05 (+3.85%)
Precision BioSciences: Q3 Earnings Snapshot

Precision BioSciences: Q3 Earnings Snapshot

DTIL : 4.05 (+3.85%)
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

- Late-breaking oral presentation at the Liver Meeting ® 2025 to feature new data from multiple cohorts of the Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis...

DTIL : 4.05 (+3.85%)
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases,...

DTIL : 4.05 (+3.85%)
H.C. Wainwright Sticks to Its Buy Rating for Precision BioSciences (DTIL)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Precision BioSciences, with a price target of $60.00. The company’s shares opened today at $5.91.Elevate Your...

DTIL : 4.05 (+3.85%)
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies...

DTIL : 4.05 (+3.85%)

Business Summary

Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.

See More

Key Turning Points

3rd Resistance Point 4.53
2nd Resistance Point 4.33
1st Resistance Point 4.19
Last Price 4.05
1st Support Level 3.84
2nd Support Level 3.64
3rd Support Level 3.50

See More

52-Week High 8.82
Fibonacci 61.8% 6.88
Fibonacci 50% 6.28
Fibonacci 38.2% 5.69
Last Price 4.05
52-Week Low 3.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar